Diversity Hemex Team
Meet Brandon García, our newest intern at HEMEX
New Year's resolutions can be a powerful way to make positive changes in life and [...]
Continue reading
Investment Press Release
Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Clinical Development Innovation Investment Press Release
Resistell recruits first patients for international clinical study
Resistell recruits first patients for international clinical study
Continue reading
Innovation Investment Press Release
Reaching for the stars – ASPIVIX receives 510(k) clearance of Carevix™ from the U.S. FDA
HEMEX is proud to announce that our portfolio company ASPIVIX has received 510(k) clearance of [...]
Continue reading
Innovation Investment Press Release
Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant
We are thrilled to share that HEMEX is part of the investment consortium financing the [...]
Continue readingFollowing up on our diversity series, this time we would like you to meet two of our newest additions to the team, Yaozi and Mohamed. Two energetic young people who are always looking for new challenges. Would you like to know a little more about their lives and how they just ended up at HEMEX? […]
In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”. As a founder and […]
Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize. The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in […]
Our portfolio company ARTIDIS announces today promising data from their first prospective study conducted at the Breast Center in Basel, Switzerland. The spin-off from the Biozentrum at the University of Basel has succesfully developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. HEMEX AG is a privately-owned Swiss investment and consulting company headquartered […]